Mike Sharma, MD

The professor of medicine at McMaster University discussed findings from OCEANIC-STROKE, where treatment with asundexian reduced the risk of recurrent stroke without increasing major hemorrhage in patients. [WATCH TIME: 4 minutes]

In this final iteration, neurologist Mike Sharma, MD, reflects on how rapid diagnostics, comprehensive vascular management, and novel therapies are redefining the approach to secondary stroke prevention.

In episode 3, Mike Sharma, MD, reviews findings from the phase 2 PACIFIC-STROKE trial and explains how its results informed the design and dose selection for OCEANIC-STROKE.

This segment outlines the objectives, patient population, and conduct of the phase 3 OCEANIC-STROKE trial evaluating asundexian for secondary stroke prevention.

In this initial episode, neurologist Mike Sharma, MD, explains the biological rationale for inhibiting factor XIa and how its unique mechanism may allow stroke prevention with minimal bleeding risk.